RecruitingNCT07114874
This study is looking at evaluate the long-term safety of NBI-1117568 in adults with schizophrenia. Taking part may give some people access to NBI-1117568, but direct benefit is not guaranteed.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, Romania, Serbia, United States
- Sponsor
- Neurocrine Biosciences
- Condition
- Schizophrenia
Active Not RecruitingNCT06791122
This study is looking at gather new information on CT-155 for people with Schizophrenia. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- Boehringer Ingelheim
- Condition
- Schizophrenia
RecruitingNCT05945602
This observational study is following people with Schizophrenia Spectrum Disorders to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 75 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Schizophrenia
RecruitingNCT03817502
This study is looking at evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 13 Years to 17 Years
- Countries
- Bulgaria, Colombia, Mexico, Romania, Russian Federation, Serbia, Ukraine, United States
- Sponsor
- Gedeon Richter Plc.
- Condition
- Schizophrenia
Not Yet RecruitingNCT07075237
This study is looking at whether Paliperidone Palmitate Injection (PP1M) can help people with Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- China
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
- Condition
- Schizophrenia
RecruitingNCT06336382
This study is looking at confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing for people with Late Onset Schizophrenia or Delusional Disorder. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 65 Years to 85 Years
- Countries
- United States
- Sponsor
- Jeremy Koppel
- Condition
- Schizophrenia
Not Yet RecruitingNCT07194460
This study is comparing Peripheral Magnetic Stimulation (PMS) with Sham control group for people with Schizophrenia. Participants receive Peripheral Magnetic Stimulation (PMS) or Sham control group and complete study visits and assessments.
SchizophreniaOtherFrom 60 Years to 80 Years
- Countries
- Global
- Sponsor
- Yuntong Zhang
- Condition
- Schizophrenia
RecruitingNCT05958875
This study is looking at whether a digital support tool can help people with Schizophrenia and Related Disorders or Early Treatment-Resistance. Participants receive a study treatment and complete follow-up visits and assessments.
SchizophreniaOtherFrom 18 Years to 70 Years
- Countries
- Austria, Germany, Italy, Spain, United Kingdom
- Sponsor
- Dr. Inge Winter
- Condition
- Schizophrenia
RecruitingNCT05389787
This study is looking at investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients for people with Schizophrenia, Cerebellar Function, or Condition. Some participants may receive Sham instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- Northwell Health
- Condition
- Schizophrenia
RecruitingNCT06191965
This observational study is following people with Schizophrenia and Related Disorders, Mitochondrial Alteration, or Cognitive Impairment to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 35 Years
- Countries
- Switzerland, United States
- Sponsor
- Mclean Hospital
- Condition
- Schizophrenia
RecruitingNCT07192042
This observational study is following people with Schizophrenia and Schizophrenia Spectrum Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 20 Years to 70 Years
- Countries
- Taiwan
- Sponsor
- Taipei Medical University Shuang Ho Hospital
- Condition
- Schizophrenia
RecruitingNCT07191483
This observational study is following people with Cognitive Impairment Associated With Schizophrenia to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Kynexis B.V.
- Condition
- Schizophrenia
RecruitingNCT07139171
This observational study is following people with Schizophrenia to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- China
- Sponsor
- Tianjin Anding Hospital
- Condition
- Schizophrenia
Active Not RecruitingNCT05719116
This study is looking at whether Physical exercise can help people with Psychosis. Participants take part in the therapy or support program and complete follow-up questionnaires or assessments.
SchizophreniaOtherOver 18 Years
- Countries
- Norway
- Sponsor
- Solli Distriktspsykiatriske Senter
- Condition
- Schizophrenia
RecruitingNCT07105098
This study is looking at care and outcomes for people with Schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, Romania, United States
- Sponsor
- Neurocrine Biosciences
- Condition
- Schizophrenia
Enrolling By InvitationNCT04007510
This study is looking at whether a digital support tool can help people with First Episode Psychosis. Participants receive a study treatment and complete follow-up visits and assessments.
SchizophreniaOtherFrom 8 Years to 40 Years
- Countries
- United States
- Sponsor
- University of California, Davis
- Condition
- Schizophrenia
RecruitingNCT05435300
This study is looking at examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia for people with Schizophrenia or Schizoaffective. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherOver 18 Years
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health
- Condition
- Schizophrenia
Not Yet RecruitingNCT03575000
This study is looking at be a small, short-duration pilot focusing on safety and tolerability for people with Schizophrenia or PreDiabetes. Participants receive a study treatment and complete follow-up visits and assessments.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- VA Pittsburgh Healthcare System
- Condition
- Schizophrenia
Active Not RecruitingNCT04318977
This study is looking at care and outcomes for people with Negative Symptoms With Primary psychosis or Schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 18 Years to 75 Years
- Countries
- Czech Republic, Germany
- Sponsor
- University of Regensburg
- Condition
- Schizophrenia
RecruitingNCT05299749
This study is comparing stg-rt-fMRI-Neurofeeback with sham-rt-fMRI for people with Schizophrenia, Auditory Hallucination, or Treatment-resistant Schizophrenia. Participants receive stg-rt-fMRI-Neurofeeback or sham-rt-fMRI and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Boston VA Research Institute, Inc.
- Condition
- Schizophrenia
RecruitingNCT07122895
This study is looking at examine the sex difference in the efficacy of an NMDA-enhancer (NMDAE) for the treatment of negative symptoms in schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 20 Years to 65 Years
- Countries
- Taiwan
- Sponsor
- China Medical University Hospital
- Condition
- Schizophrenia
Not Yet RecruitingNCT07146802
This study is looking at compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis for people with Schizophrenia Spectrum Disorder. Participants take part in psychoeducation and complete follow-up assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Global
- Sponsor
- University Hospital, Strasbourg, France
- Condition
- Schizophrenia
Enrolling By InvitationNCT07173192
This study is comparing Individual empowerment program with control group for people with Schizophrenia. Participants receive Individual empowerment program or control group and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Turkey
- Sponsor
- Istanbul Arel University
- Condition
- Schizophrenia
RecruitingNCT06821945
This study is looking at care and outcomes for people with Schizophrenia. Taking part may give some people access to BR5402A, but direct benefit is not guaranteed.
SchizophreniaOtherOver 19 Years
- Countries
- South Korea
- Sponsor
- Boryung Pharmaceutical Co., Ltd
- Condition
- Schizophrenia
Not Yet RecruitingNCT07152184
This study is looking at whether a digital support tool can help people with With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, or Schizophrenia Spectrum and Other psychosis. Participants receive a study treatment and complete follow-up visits and assessments.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- Global
- Sponsor
- University Hospital, Strasbourg, France
- Condition
- Schizophrenia